Increased risk for stress urinary incontinence in women with postmenopausal hormone therapy
| العنوان: | Increased risk for stress urinary incontinence in women with postmenopausal hormone therapy |
|---|---|
| المؤلفون: | Päivi Rahkola-Soisalo, Mika Gissler, Hanna Savolainen-Peltonen, Fabian Hoti, Tomi S. Mikkola, Olavi Ylikorkala, Pia Vattulainen |
| المساهمون: | HUS Gynecology and Obstetrics, Department of Obstetrics and Gynecology |
| المصدر: | International Urogynecology Journal. 30:251-256 |
| بيانات النشر: | Springer Science and Business Media LLC, 2018. |
| سنة النشر: | 2018 |
| مصطلحات موضوعية: | MENOPAUSE, medicine.medical_specialty, Norpregnenes, medicine.drug_class, Urinary Incontinence, Stress, Urology, medicine.medical_treatment, 030232 urology & nephrology, Urinary incontinence, Tibolone, Intrauterine device, 03 medical and health sciences, 0302 clinical medicine, Risk Factors, 3123 Gynaecology and paediatrics, Humans, Medicine, Medroxyprogesterone acetate, Registries, Hormone therapy, Finland, 030219 obstetrics & reproductive medicine, Estradiol, Stress urinary incontinence, business.industry, Obstetrics, Incidence (epidemiology), Estrogen Replacement Therapy, Obstetrics and Gynecology, Estrogens, Middle Aged, medicine.disease, 3. Good health, Postmenopause, Menopause, ESTROGEN, FREE VAGINAL TAPE, Estrogen, Female, medicine.symptom, business, medicine.drug |
| الوصف: | Introduction and hypothesisThe impact of estradiol-based hormone therapy (HT) on the incidence of stress urinary incontinence (SUI) is unknown. Therefore, we compared the use of such HT regimens and tibolone in women with and without SUI.MethodsThe women with a history of SUI operation (N=15,002) were identified from the Finnish National Hospital Discharge Register, and the control women without such an operation (N=44,389) from the Finnish Central Population Register. The use of HT was traced from the National Drug Reimbursement Register, and the odd ratios (ORs) with 95% confidence intervals (95% CIs) for SUI were calculated by using the conditional logistic regression analysis.ResultsThe cases had used any HT more often than the controls. The use of systemic estradiol-only or estradiol-progestin therapy was accompanied by an increased SUI risk (OR 3.8, 95% CI: 3.6-4.0 and OR 2.7, 95% CI: 2.6-2.9 respectively). The use of estradiol with noretisterone acetate showed a higher risk of increase than that with medroxyprogesterone acetate. Age over 55years at the initiation of systemic HT was accompanied by a higher SUI risk increase than that under 55years of age. The use of tibolone, an estradiol + levonorgestrel-releasing intrauterine device, or vaginal estradiol also increased the risk.ConclusionsThe use of HT regimens may predispose to the de novo development or worsening of pre-existing SUI. Thus, caution is needed when these regimens are prescribed to women with mild stress-related urine leakage or with established SUI risk factors. |
| تدمد: | 1433-3023 0937-3462 |
| DOI: | 10.1007/s00192-018-3682-7 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::000aabd5853d48fa0d3ed07e05f92e28 https://doi.org/10.1007/s00192-018-3682-7 |
| Rights: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....000aabd5853d48fa0d3ed07e05f92e28 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14333023 09373462 |
|---|---|
| DOI: | 10.1007/s00192-018-3682-7 |